How Journals and Sponsors Shape Open Access in Clinical Trial Publication

Introduction: Why Open Access is Now Non-Negotiable

Open access (OA) has moved from being an academic preference to a clinical trial mandate. Regulatory agencies, funding bodies, and public advocacy groups are demanding increased transparency and wider availability of trial data. At the center of this movement are journal publishers and study sponsors, whose open access policies shape how, when, and where clinical trial results are published and accessed.

This article dives into the policies enforced by top medical journals and sponsors, the legal and ethical mandates around data dissemination, and the strategic decisions pharma professionals must make to stay compliant with evolving expectations.

Types of Open Access Models Explained

Before exploring specific policies, it’s crucial to understand the main OA models that journals and sponsors support:

• Gold Open Access: Articles are immediately free upon publication. Often involves an Article Processing Charge (APC).
• Green Open Access: Authors self-archive a version (pre-print or post-print) in a public repository after an embargo period.
• Hybrid Access: Subscription journals offer optional open access for individual articles upon payment of APC.
• Bronze Access: Articles are free to read but lack a clear reuse license.

Most clinical trial sponsors favor Gold or Green models to ensure compliance with funder mandates and transparency guidelines.

Major Sponsor Requirements for Open Access

Pharmaceutical sponsors and public agencies have begun enforcing open access publication as a formal requirement. Below is a snapshot of leading mandates:

Open Access Mandates from Major Journals

Leading medical journals have differing OA policies that authors must navigate:

• The BMJ: Full Gold OA journal. Mandates CC-BY license for research articles.
• NEJM: Subscription-based with optional OA for selected articles (high APC).
• The Lancet: Hybrid model. OA allowed with Plan S-aligned license and payment.
• JAMA: Permits Green OA after embargo. Offers OA for funder-mandated papers.
• PLOS ONE: Gold OA journal. No subscription content. APC applies to all.

Authors publishing trial results must align journal selection with sponsor obligations and transparency goals.

Plan S and the Rise of Funder-Led Publishing Requirements

Plan S is a coalition of funders including the European Commission, Wellcome Trust, and others requiring that all research they fund be published in compliant OA journals or platforms. Requirements include:

• Immediate open access without embargo
• Use of Creative Commons Attribution License (CC BY)
• Deposition in approved repositories
• Transparency in APC pricing

For clinical trial teams working under these funders, failing to publish in a compliant venue may jeopardize future funding.

Case Example: NIH-Funded Oncology Trial

A multicenter oncology trial funded by the NIH completed in 2022. As per NIH’s Public Access Policy, the manuscript was submitted to a hybrid journal that did not offer immediate open access. The team faced the following challenges:

• Delayed deposit of the accepted manuscript in PubMed Central
• Need to revise the publishing agreement to enable Green OA
• Inclusion of proper grant acknowledgment and NIH grant number

Ultimately, compliance was achieved after coordination with the publisher and NIH Manuscript Submission system (NIHMS).

Embargo Periods: How Long Can Access Be Delayed?

Embargoes refer to the time between article publication and when it becomes freely accessible in a public repository. Funders and journals vary:

• NIH: 12 months maximum
• Wellcome: No embargo allowed
• EC Horizon: Immediate access required
• NEJM: 6 months common unless OA option selected

Trial sponsors must integrate embargo planning into their publication strategy to avoid non-compliance.

Journals vs Repositories: Parallel Dissemination Strategy

Most funders allow dual routes of dissemination:

1. Journal Publication: Peer-reviewed, formal publication
2. Repository Submission: Depositing accepted manuscript in platforms like PubMed Central, Europe PMC, or institutional repositories

For example, a trial published in JAMA may have its accepted version archived in Europe PMC under funder guidelines. Both routes contribute to visibility and access.

Publication SOPs for Sponsors

Pharma companies and CROs must maintain internal SOPs that align with global OA mandates. These SOPs often include:

• Pre-submission compliance checks
• Preferred journal list with OA compatibility
• Coordination with medical writers and authors
• Archiving requirements in corporate repositories
• Communication with funders on embargo negotiations

Failure to follow these SOPs can result in inspection findings under GPP3 (Good Publication Practice) guidelines.

Best Practices for Trial Teams

• Check funder OA mandates before selecting a journal
• Choose journals indexed in trial registries or connected to ORCID/iCite
• Budget for APCs in grant or sponsor funding plans
• Document all communications with publishers regarding access rights
• Use institutional OA advisors to resolve legal conflicts

Planning ahead minimizes the risk of non-compliance and improves the trial’s dissemination timeline.

Conclusion: Ensuring Access to Scientific Knowledge

Open access policies are no longer optional — they are legally and ethically mandated across the global clinical trial landscape. Journals and sponsors play pivotal roles in ensuring trial outcomes are not locked behind paywalls. By understanding the varying models, planning for APCs, and aligning with sponsor and funder expectations, clinical research teams can ensure that trial results reach the widest possible audience — fostering public trust, advancing science, and meeting transparency goals.

Ensuring Ethical Publication of Clinical Trials Through GPP Guidelines

Introduction to GPP: Why Ethical Publication Matters

Clinical trial publications shape medical guidelines, regulatory decisions, and patient care. Ethical lapses such as ghostwriting, selective reporting, or sponsor bias can undermine the scientific integrity of published results. To address these concerns, the International Society for Medical Publication Professionals (ISMPP) developed the Good Publication Practice (GPP) guidelines, currently in its third version (GPP3).

These guidelines aim to promote transparency, responsible authorship, and ethical sponsor engagement in the publication of clinical trial data. GPP applies to pharmaceutical companies, contract research organizations (CROs), academic collaborators, and medical writers involved in the publication planning and dissemination process.

Core Principles of GPP3

GPP3 outlines the ethical standards and operational expectations for preparing and publishing trial-related manuscripts. Core principles include:

• Transparency: Disclose sponsor involvement, funding sources, and data access rights clearly.
• Accountability: Ensure all listed authors meet the ICMJE authorship criteria.
• Accuracy: Report trial results honestly, without bias, spin, or data manipulation.
• Timeliness: Publish results in a timely manner consistent with regulatory disclosure timelines.
• Respect for contributors: Acknowledge the roles of statisticians, writers, and investigators.

These standards align with ICMJE’s Uniform Requirements and complement regulatory requirements from FDA, EMA, and WHO registries.

Authorship Ethics: Avoiding Misconduct

One of the most critical elements in ethical publishing is defining who qualifies as an author. According to both GPP and ICMJE guidelines, authors must meet all of the following criteria:

• Substantial contribution to study design, data analysis, or interpretation
• Drafting or revising the article critically for intellectual content
• Approval of the final version for publication
• Accountability for the accuracy and integrity of the published content

GPP3 strongly discourages ghostwriting—where individuals contribute without acknowledgment—or guest authorship—where individuals are credited without meaningful contribution. Both practices are considered publication misconduct.

Managing Sponsor Involvement and Independence

Sponsors often fund and manage trials, but their role in publication must be disclosed and regulated. Ethical sponsor practices include:

• Allowing authors full access to data or summary-level analyses
• Refraining from controlling the publication’s message or conclusions
• Disclosing conflicts of interest (COIs) related to employment, funding, or stock ownership
• Ensuring transparency about editorial assistance from medical writers

Example: In a multi-site trial on a novel anticoagulant, the sponsor may support writing through an external medical communication agency. However, all authors should approve the content, and the writer’s name and funding source must be disclosed.

Publication Planning and Documentation

Ethical publication also involves organized planning. GPP3 recommends sponsors and authors collaboratively develop a publication plan that includes:

• A publication timeline linked to trial milestones (e.g., database lock, CSR finalization)
• A list of planned abstracts, posters, and manuscripts
• Defined roles and responsibilities for each author and contributor
• A process for conflict resolution and content approval

Publication plans help avoid publication bias by documenting the intent to publish all prespecified outcomes, regardless of result significance. Many sponsors now maintain internal SOPs to govern these workflows.

External Guidelines Complementing GPP

GPP guidelines work in tandem with several other international frameworks:

• EU CTR: Requires summary results and layperson summaries within 12 months of trial completion
• FDAAA 801: Mandates results reporting on ClinicalTrials.gov
• ICMJE: Sets criteria for authorship and trial registration
• WHO ICTRP: Advocates for global result disclosure standards

GPP-compliant sponsors should ensure their practices do not contradict these overlapping obligations.

Role of Medical Writers and Review Committees

Medical writers play an integral role in transforming complex trial data into clear, accurate, and ethical publications. GPP encourages acknowledgment of their work and insists on:

• Documentation of writing contributions in the manuscript or submission form
• Verification that writers had no role in data manipulation or outcome shaping
• Confirmation that writers received direction from authors, not solely from the sponsor

Meanwhile, publication review committees (PRCs) at many organizations ensure that all manuscripts meet internal quality standards and GPP principles before journal submission.

Common Violations and Their Consequences

GPP violations can lead to severe reputational and regulatory consequences. Common violations include:

• Failing to disclose sponsor involvement
• Publishing only favorable outcomes (publication bias)
• Suppressing trial data or delaying negative result publication
• Adding honorary or ghost authors
• Not declaring writer contributions or financial support

Example: In a 2020 audit of 75 industry-sponsored trials published in top journals, over 20% failed to disclose medical writing support—despite involvement. Journals like The Lancet and BMJ have since tightened disclosure policies.

Conclusion: Making GPP a Standard Practice

The GPP guidelines represent a foundational framework for ethical trial result publication. Implementing GPP practices not only ensures compliance but fosters trust among peers, regulators, patients, and the public. Sponsors, CROs, and academic institutions should integrate GPP into their publication SOPs, training, and governance systems.

As clinical trial disclosure becomes increasingly regulated, ethical publication isn’t just a best practice—it’s a moral, scientific, and legal imperative. Upholding GPP principles safeguards the value of medical research and protects the patients whose participation makes it possible.